Back to Treatments

Treatment

Pembrolizumab + Lenvatinib

1
Conditions
26
Trials
355
Participants
30%
Average Safety

Condition Evidence

Kidney cancer

26 trials · 355 participants

90% effectiveness · 30% safety
Pembrolizumab + Lenvatinib | DFDA